Catalyst

Slingshot members are tracking this event:

Effective March 10, Gilead Sciences Chairman and CEO John Martin, Ph.D. will transition to the role of Executive Chairman, and President & COO John Milligan, Ph.D. will be promoted to CEO.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD

100%

Additional Information

Additional Relevant Details John Martin joined Gilead in 1990 and was appointed Chief Executive Officer in 1996 and Chairman of the Board in 2008. John Milligan also joined Gilead in 1990 and was appointed Chief Operating Officer in 2007 and President in 2008.“John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear – and the vision he has set will continue with his contributions as Executive Chairman,” said John Cogan, PhD, Gilead’s Lead Independent Director.
http://www.gilead.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 29, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ceo, Managment Change